Прогностические факторы, влияющие на показатели выживаемости􀀂 у больных старческого возраста с метастатическим почечноклеточным раком

Семенов Дмитрий Владимирович; Орлова Рашида Вахидовна; Широкорад Валерий Иванович; Кострицкий Станислав Викторович; Кононец Павел Вячеславович

��-�� . 2024. �. 5, � 3. �. 31-38

https://doi.org/10.37748/2686-9039-2024-5-3-3

https://elibrary.ru/gskqjk

3.1.6. ��, ��

��

�� , �� ..

� �� ..

�� ..

�. �. ��1,2 , �. �. ��1,2, �. �. ��3, �. �. ��3, �. �. ��4

1 �� -�� , �. ��-��, ��

2 �� , �. ��-��, ��

3 �� 62 �� , �. ��,

��

4 �� . �. ��

�� , �. ��, ��

sema.69@mail.ru

��

�� .

�� c

�� -�� (��) � �� . 75 ��.

�� .

� �� 77 �� c �� . 75 ��,

�� 62 �. ��

��

�. ��-��

� 2006

�� 2019

��. ��

��

�� , �� -��, ��

��. ��

�� (Survival

Analysis)

� ��

��

�� -��.

��.

� �� IMDC � �� c �� . 75 �� 20,8

%

��, �� 6,5

%. �� 3 � 5-�� 35,8

% � 21,2

%.

�� . 75 ��, ��, ��

�� ECOG c�� (p

< 0,001), �� (p

= 0,01), ��

�� Fuhrman (p

= 0,003), �� (p

= 0,045), �� (p

< 0,001), �� IMDC (p

= 0,042) � ��

�� (p = 0,014).

��.

��, �� . 75 ��, ��

�� ,

�� , ��

��,

��

� ��

��, �� IMDC, � �� .

�� c

�� .

�� : �� -�� , �� , ��

�� : �� . �., �� . �., �� . �., �� . �., �� . �. �� , ��

�� . ��-��

��. 2024; 5(3): 31-38. https://doi.org/10.37748/2686-9039-2024-5-3-3, https://elibrary.ru/gskqjk

�� : �� .�.�., ��

�� , �. ��-��, �� ; �� , ��

�� , �. ��-��, ��

��: 199034, �� , �. ��-��, �� , �. 7/9

��: 198255, �� , �. ��-��, ��. ��, �. 56

E-mail: sema.69@mail.ru

ORCID: https://orcid.org/0000-0002-4335-8446

SPIN: 2342-6530, AuthorID: 202214

ResearcherID: KQU-5717-2024

Scopus Author ID: 58596081800

�� : � �� , ��

�� (World Medical Association Declaration of Helsinki, 1964, ��. 2013). ��

�� (�� 2356 �� 20.05.2022 �.). ��

��

��: ��

�� :

��

��,

��

�� 02.03.2024; �� 31.05.2024; �� 24.07.2024

� �� . �., �� . �., �� . �., �� . �., �� . �., 2024

South Russian Journal of Cancer. 2024. Vol. 5, No. 3. P. 31-38

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

https://doi.org/10.37748/2686-9039-2024-5-3-3

https://elibrary.ru/gskqjk

ORIGINAL

ARTICLE

Prognostic factors influencing survival rates in elderly patients with metastatic renal..

cell carcinoma..

D.

V. Semenov1,2 , R. V. Orlova1,2, V. I. Shirokorad3, S. V. Kostritsky3, P. V. Kononets4

1 St. Petersburg State University, St. Petersburg, Russian Federation

2 City Clinical Oncological Dispensary, St. Petersburg, Russian Federation

3 Moscow City Oncological Hospital No. 62 of the Moscow City Health Department, Moscow, Russian Federation

4 N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation

sema.69@mail.ru

ABSTRACT

Purpose

of the

study.

To determine the influence of prognostic factors on survival rates

in patients

with mRCC aged . 75

years.

Materials and methods.

A retrospective study included 77 mRCC patients aged . 75 years who received systemic therapy

at the Municipal Oncologic Hospital No. 62 in Moscow and the Municipal

Oncologic Dispensary in St.

Petersburg from 2006

to 2019. Clinical data from medical records were obtained and analyzed retrospectively, all patients underwent clinical, laboratory,

and pathomorphological examination. Patients' survival rates were evaluated using the statistical method of survival

time analysis (Survival Analysis). Descriptive characteristics of survival time were calculated in the form of life tables, and

Kaplan-Meier curves were constructed.

Results.

In the present study, a favorable prognosis according to International Metastatic Renal Cell Carcinoma Database

Consortium (IMDC)was noted in 20.8

% of patients with mRCC aged . 75 years; 6.5

% had solitary metastases. The 3- and

5-year survival rates were 35.8

% and 21.2

%.

In single-factor analysis in mRCC patients . 75 years of age, it was found that ECOG status (p

< 0.001), histological subtype

(p

= 0,01), Fuhrman grade of tumour differentiation (p

= 0.003), type of metastases (p

= 0.045), liver metastases (p

< 0.001),

IMDC prognosis (p = 0.042) and nephrectomy (p = 0.014).

Conclusion.

In

a multivariate

analysis, factors

affecting survival

in

patients

with

mRCC aged . 75

years

included sex, histologic

subtype, number of metastases, bone

and

lymph

node

metastases, IMDC

prognosis, and

radiation

therapy and

nephrectomy.

Further

studies are needed to

identify additional personalized prognostic

factors in elderly patients with metastatic

renal cell

carcinoma (mRCC).

Keywords: metastatic renal cell carcinoma, overall survival rate, elderly patients

For citation: Semenov D. V., Orlova R. V., Shirokorad V. I., Kostritskiy

S. V., Kononets

P. V. Prognostic factors

influencing

survival rates

in elderly

patients

with

metastatic renal cell carcinoma. South Russian Journal of Cancer. 2024;

5(3): 31-38. https://doi.org/10.37748/2686-9039-2024-5-3-3, https://elibrary.ru/gskqjk

For correspondence: Dmitry V. Semenov � Cand. Sci. (Med.), Associate Professor of the Department of Oncology, Faculty of Medicine, Saint Petersburg

State University, Saint Petersburg, Russian Federation; Physician in the Oncourology Department, City Clinical Oncologic Dispensary, Saint Petersburg, Saint

Petersburg, Russian Federation

Address: 7/9 Universitetskaya Embankment, Saint Petersburg 199034, Russian Federation

Address: 56 Veterans Ave., Saint Petersburg 198255, Russian Federation

E-mail: sema.69@mail.ru

ORCID: https://orcid.org/0000-0002-4335-8446

SPIN: 2342-6530, AuthorID: 202214

ResearcherID: KQU-5717-2024

Scopus Author ID: 58596081800

Compliance with ethical standards: the study adhered to the ethical principles outlined in the World Medical Association Declaration of Helsinki (1964,

revised in 2013). The research was approved by the Ethics Committee of the Saint Petersburg City Clinical Oncological Dispensary (protocol No. 2356 dated

May 20, 2022). Informed consent was obtained from all study participants

Funding: this work was not funded

Conflict of interest: the authors declare that there are no obvious and potential conflicts of interest associated with the publication of this article

The article was submitted 02.03.2024; approved after reviewing 31.05.2024; accepted for publication 24.07.2024

��-�� 2024. �. 5, � 3. �. 31-38

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

�� . �. , �� . �., �� . �., �� . �., �� . �. �� , ��

��

�� -

��

(��)

�� .

��

� 25

% ��

�� 75

�� [1]. �

��

��-�� (��)

��

�� ,

��

�� (��)

��

�� 4

�� [2, 3]. ��, ��

��

�� .

��

� ��

��, � ��

��

� � ��

��

[4]. ��

��

� ��

.

75

��

� ��

��

��, ��

�� .

�� :

��

. 75

��,

��

�� .

��

�

��

�� 77 ��

� �� . 75

��, ��

��

� 62 �. ��

� ��

�� 1. ��

��. 75 �� (n = 77), n (%)

��:

��

51 (66,2)

��

26 (33,8)

�� ECOG:

0

1

1 (1,3)

29 (37,7)

2

35 (45,5)

3 12 (15,6)

�� :

��

64 (83,1)

13 (16,9)

�� :

G1

18 (23,4)

G2

27 (35,1)

G3

32 (41,6)

�� :

��

53 (68,8)

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

��

24 (31,2)

�� :

��

5 (6,5)

��

27 (35,1)

��

45 (58,4)

�� IMDC:

��

16 (20,8)

��

32 (41,6)

��

29 (37,7)

�� :

� ��

48 (62,3)

� ��

26 (33,8)

� �� 6

(7,8)

� ��

21 (27,3)

��

71 (92,2)

��

11 (14,3)

�� 10

(13)

South Russian Journal of Cancer 2024. Vol. 5, No. 3. P. 31-38

Semenov D. V. , Orlova R. V., Shirokorad V. I., Kostritskiy S. V., Kononets P. V. Prognostic factors influencing survival rates in elderly patients with metastatic renal

cell carcinoma

�� . ��-��

2006 ��

2019 �.

��

��. ��

�� .

��

� �� 1.

Survival curves for Overall

Based on Kaplan-Meier estimates

1.00

Probability

0.75

0.50

0.25

0

01224364860

Number

at risk

Time (months)

AII

77

62

48

28

18

15

3-�� : 35,8 %

5-�� : 21,2 %

��. 1. �� (��) �� . 75

��

(n

= 77)

Survival curves for Histology

Based on Kaplan-Meier estimates

1.00

��

� ��

��

� �� Statistica 12

for Windows.

��

��. �� -

��, ��

��

�

�� log-rank ��;

��

��, ��

��

Cox. ��

��

. 75 ��

��, ��

�� Fuhrman, �� IMDC, ��,

�� , ��

�� .

��

��-��

��

77

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

�� . 1. ��

�� 79

(75�95)

��. ��

�� 64

(83,1

%) ��.

��, ��

��

IMDC � 16 (20,8

%), 32 (41,6

%)

� 29

(37,7

%)

��. ��, ��

Survival curves for Grade

Based on Kaplan-Meier estimates

1.00

Log-rankp = 0.0091

0

12

24

36

48

60

Number

at risk

Time (months)

Grade -

Grade 1

18

16

9

7

Grade -

Grade 2

27

23

19

12

7

5

Grade -

Grade 3

32

21

13

7

4

3

Log-rankp = 0.012

0.75

Probability

0.25

0.50

�

0

Number

at risk

Histology CKP

0

64

12

53

24

36

48

Time (months)

43

25

17

60

15

HIstology -

He CKP

13

9

5

3

1

0

3-�� :

5-�� :

3-�� : 43,2 % � 25,9 %

5-�� : 23 % � 0 %

56,2 % 46,5 % 24,5 %

43,8 % 19,4 %

��. 2. �� (��) � �� . 75 �� (�)

� �� Fuhrman (�) (n = 77)

��-�� 2024. �. 5, � 3. �. 31-38

�� . �. , �� . �., �� . �., �� . �., �� . �. �� , ��

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

��

� �� 5 (6,5

%),

27 (35,1

%) � 45 (58,4

%) �� .

�� 3

� 5-��

� ��

�� 39,7

% [29,8�52,76

%; 95

% ��]

� 21,2

%

[13,6�33,24

%;

95

%

��] ��,

Survival curves for Type

Based on Kaplan-Meier estimates

1.00

�� 32,4

[28,9�38,6

%;

95 ��] �� (��. 1).

��

� ��

��

. 75

�� , ��

�� ECOG ��-

Survival curves for Hepar

Based on Kaplan-Meier estimates

1.00

Log-rankp = 0.043

01224364860

NumberTime (months)

at risk

�� = ��-

Log-rankp < 0.0001

01224364860

NumberTime (months)

at risk

��r -

Probability

0.75

Probability

0.50

0.25

�

0

�

0

��

24

16

11

7

2

��

71

60

47

28

18

15

�� (2)

� �� (-)

�� =

��

��-53

46

37

21

16

13

��

6

2

1000

��

� �� (+)

3-�� :

5-�� :

3-�� :

5-�� :

1-�� :

43,6 % � 30,7 %

27,0 % � 8,8 %

43,1 %

223,1 %

33,3%

��. 3. �� (��) � �� . 75 �� (�) � ��

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

� �� (�) (n = 77)

Survival curves for IMDC

Survival curves for CN

Based on Kaplan-Meier estimates

1.00

Log-rankp= 0.00032

01224364860

Log-rankp = 0.0096

01224364860

Probability

0.75

0.50

Probability

0.75

0.50

0.25

�

0

Number

at risk

Time (months)

Number

at risk

Time (months)

IMDC ��

��

IMDC ��

16

32

29

15

27

20

13

23

12

9

14

5

7

4

7

6

2

CN -��

(+)

CN -��3

(-)

71

6

59

3

46

2

27

1

18

0

15

0

3-�� :

64,9 % 47,2 % 18,0 %

5-�� :

50,5 % 20,2 % 7,2 %

3-�� :

41,6 % 16,7 %

5-�� :

23,1 % 0 %

��. 4. �� (��)

� �� . 75

�� IMDC (�)

� �� (�)

(n

= 77)

South Russian Journal of Cancer 2024. Vol. 5, No. 3. P. 31-38

Semenov D. V. , Orlova R. V., Shirokorad V. I., Kostritskiy S. V., Kononets P. V. Prognostic factors influencing survival rates in elderly patients with metastatic renal

cell carcinoma

�� 2. �� . 75 �� (n = 77)

(�� )*

�� (95% �� )

��

��:

��

�

0,62 (0,37�1,05, p

=

0,077)

�

0,27 (0,16�0,46, p

<

0,001)

�� ECOG

0

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

1

2

3

�

20379783,9 (0,00-Inf, p

=

0,997)

38320352,5 (0,00-Inf, p

=

0,997)

82331370,5 (0,00-Inf, p

=

0,996)

�

41895,8 (24218�1572477,23, p

<

0,001)

69920,5 (41671,28�117320,25, p

< 0,001)

112174,0 (53540,28�235019,58, p

<

0,001)

�� :

��

�

2,19 (1,17�4,09, p

=

0,014)

�

1,92 (1,02�3,60, p

=

0,043)

��

��:

G1

G2

G3

�

1,74 (0,90�3,36, p

=

0,100)

2,71 (1,40�5,25, p

=

0,003

�

1,43 (0,86�2,36, p

=

0,169)

1,38 (0,83�2,32, p

=

0,218)

Metastasis type:

��

�

0,59 (0,35�0,99, p

=

0,045)

�

1,22 (0,71�2,08, p

=

0,478)

�� :

��

�

0,64 (0,24�1,71, p

=

0,372)

1,33 (0,52�3,42, p

=

0,553)

�

0,59 (0,35�1,00, p

=

0,050)

1,66 (1,00�2,73, p

=

0,049)

�� :

��

�

1,58 (0,38�6,64, p

=

0,532)

�

1,29 (0,81�2,08, p

=

0,139)

�� :

��

�

1,17 (0,69�1,98, p

=

0,557)

�

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

3,09 (1,82�5,23, p

<

0,001)

�� :

��

�

6,68 (2,74�16,28, p

<

0,001)

�

1,86 (0,74�4,69, p

=

0,186)

��

� �� :

��

�

1,16 (0,68�1,97, p

=

0,595)

�

0,54 (0,31�0,93, p

=

0,026)

�� IMDC:

��

�

4,00 (1,93�8,29, p

<

0,001)

2,07 (1,03�4,18, p

=

0,042)

�

1,94 (1,13�3,33, p

=

0,016)

1,93 (1,17�3,20, p

=

0,010)

�� :

��

�

0,99 (0,44�2,20, p

=

0,979)

�

0,28 (0,12�0,64, p

=

0,002)

��:

��

�

2,95 (1,25�6,99, p

=

0,014)

�

6,08 (2,54�14,58, p

<

0,001)

��

0,41 (0,05�3,53, p

=

0,419)

0,65 (0,28�1,46, p

=

0,323)

��: � �� , ��

��-�� 2024. �. 5, � 3. �. 31-38

�� . �. , �� . �., �� . �., �� . �., �� . �. �� , ��

��

(p < 0,001), �� (p =

0,01),

��

Fuhrman

(p

= 0,003),

��

(p

= 0,045),

��

� �� (p

< 0,001), �� IMDC (p

= 0,042)

� �� (p

= 0,014) (��. 2,

��. 2�4).

��

�� 34,4

[30,0�44,6; 95

% ��]

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

� 21,2

[10,4�NA; 95

% ��] �� ,

� �� G1, G2 � G3 �� 46,4 [34,4�NA; 95

% ��],

33,4

[26,9�51; 95

% ��] � 21,7

[13,9�31,6; 95

% ��]

�� .

��

� ��

�� 33 [29,1�46,9;

95

%

��]

� 23,7 [12�44,6; 95

% ��] �� ,

� ��

�� 33,4 [29,1�44,6;

95

%

��] � 5,1 [3,5�NA;

95

% ��] �� .

��

�� , ��

� �� 65,2 [35,9�

NA; 95

% ��], 35,8

[29�46,3; 95

% ��] � 21,2

[13,7�

31,1; 95

% ��] �� , � ��

�� 32,6 [29�44,6; 95

%

��] � 10

[5�NA; 95

% ��] �� .

�� [HR = 0,27

(95

%

�� = 0,16�0,46],

ECOG ��

[HR = 112174,0

(95

% �� =

53540,28�235019,58], ��

�� [HR

= 1,92

(95

% �� = 1,02�3,60], ��

�� [HR = 1,66

(95

% �� = 1,00�2,73], ��

�

�� [HR = 3,09 (95

%

�� = 1,82�5,23]

�

��

�� [HR

=

0,54

(95

% ��

=

0,31�0,93],

��

�� IMDC

[HR

=

1,93

(95

% �� =

1,17�3,20],

� �� [HR = 0,28

(95

% ��

=

0,12�0,64] � �� [HR

=

6,08

(95

%

�� = 2,54�14,58] ��

��

��,

��

� ��

�� (��. 2).

��

� ��

��

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

�� , � 25

% ��

�� 75

�� [1].

�

��

�� R.

Kanesvaran

� ��. ��

��

[5]. �

��

3

� 5-�� . 75

��

35,8

% � 21,2

%. �

�� Ryuichi Mizuno � ��.

��

IMDC,

��

��,

� ��

�� , ��

��

�� [6]. � ��

�� 35,1

% ��, 1/5

��

� ��

�� IMDC, ��

�� .

��

�� [7]. ��

��

�� .

��

�� -��

��

��.

��

��-�� ,

��

� ��

�� . �

��

� ��

��

�� [8, 9]. �

��

�� ,

��

�� .

��

�� . ��

��

�

��

�� .

��

��, ��

� ��

.

75

��, ��

��

��, ��

��, �� , ��

�

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

�� ,

��

IMDC,

�

��

�� .

��

�� c ��

��.

South Russian Journal of Cancer 2024. Vol. 5, No. 3. P. 31-38

Semenov D. V. , Orlova R. V., Shirokorad V. I., Kostritskiy S. V., Kononets P. V. Prognostic factors influencing survival rates in elderly patients with metastatic renal

cell carcinoma

��

1.

Pal SK, Vanderwalde A, Hurria A, Figlin RA. Systemic therapies for metastatic renal cell carcinoma in older adults. Drugs

Aging.

2011

Aug

1;28(8):635�649.

https://doi.org/10.2165/11592880-000000000-00000

2.

Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced

Renal Cell Carcinoma. N Engl J Med. 2021 Apr 8;384(14):1289�1300. https://doi.org/10.1056/NEJMoa2035716

3.

Xia Y, Liu X, Xu DF, Zhao CH. Exploring the feasibility of cytoreductive surgery for patients aged .75 years with metastatic

renal cell carcinoma: A population-based study. Asian J Surg. 2023 Dec;46(12):5817�5819.

https://doi.org/10.1016/j.asjsur.2023.08.157

4.

Fujiwara Y, Miyashita H, Liaw BC. First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-

oncology era: a network meta-analysis. Cancer Immunol Immunother. 2023

Jun;72(6):1355�1364.

https://doi.org/10.1007/s00262-022-03341-y

5.

Kanesvaran R, Le Saux O, Motzer R, Choueiri TK, Scotte F, Bellmunt J, et al. Elderly patients with metastatic renal cell carcinoma:

position paper from the International Society of Geriatric Oncology. Lancet Oncol. 2018 Jun;19(6):e317�326.

https://doi.org/10.1016/s1470-2045(18)30125-6

6.

Mizuno R, Yasumizu Y, Tanaka N, Takeda T, Morita S, Matsumoto K, et al. Anemia in patients . 75 years with metastatic clear

cell renal cell carcinoma: an important poor prognostic factor in the international metastatic renal cell carcinoma database

consortium model. BMC Urol. 2024 Jan 11;24(1):13. https://doi.org/10.1186/s12894-024-01403-0

7.

Quivy A, Daste A, Harbaoui A, Duc S, Bernhard JC, Gross-Goupil M, et al. Optimal management of renal cell carcinoma in

the elderly: a review. Clin Interv Aging. 2013;8:433�442. https://doi.org/10.2147/cia.s30765

8.

Teishima J, Inoue S, Hayashi T, Matsubara A. Current status of prognostic factors in patients with metastatic renal cell

carcinoma. Int J Urol. 2019 Jun;26(6):608�617. https://doi.org/10.1111/iju.13956

9.

De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, et al. Association of Systemic Inflammation Index

and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. Clin Cancer Res. 2019 Jul

1;25(13):3839�3846.

https://doi.org/10.1158/1078-0432.ccr-18-3661

�� :

��

�� .�.�., ��

��-��

��, �. ��-��, �� ; �� , ��

��

�� , �. ��-��, ��

ORCID: https://orcid.org/0000-0002-4335-8446, SPIN: 2342-6530, AuthorID: 202214, ResearcherID: KQU-5717-2024, Scopus

Author ID: 58596081800

�� .�.�., ��, ��

��-��

�� , �. ��-��, �� ; ��

�� , �. ��-��, ��

ORCID: https://orcid.org/0000-0002-9368-5517, SPIN: 9932-6170, AuthorID: 401170

�� .�.�., ��

��

� 62 �� , �. ��, ��

ORCID: https://orcid.org/0000-0003-4109-6451, AuthorID: 481900

�� -��, ��

�� 62 ��

�� , �. ��, ��

ORCID: https://orcid.org/0000-0003-4494-1489, SPIN: 1421-2469, AuthorID: 980451, ResearcherID: Y-6978-2018

��

� �.�.�., ��, �� . �. �. ��, �� ,

�� . �. ��

�� , �. ��, ��

ORCID: https://orcid.org/0000-0003-4744-6141, SPIN: 9884-6940, AuthorID: 755462

�� :

�� . �. � �� , �� , �� ;

�� . �. � �� , �� ;

�� . �. � �� , �� , �� ;

�� . �. � �� , �� ;

�� . �. � �� .